SUN PHARMA GLOBAL FZE

The Nifty Pharma index was trading 0.4 per cent down at 18568.15.

Indian companies are closely monitoring the safety of employees in Israel, a West Asian innovation hub, amid the intensifying Israel-Iran conflict. Sun Pharma, with a presence in Israel through its subsidiary Taro Pharmaceutical, is taking steps to ensure the safety and wellbeing of its employees and their families.

Sun Pharma, which operates in Israel through its subsidiary Taro Pharmaceutical, is actively monitoring the situation in the country and is taking all necessary steps to ensure safety and wellbeing of employees and their families, a company spokesperson said in an email response to ET.

The Nifty Pharma index closed 0.65 per cent down at 18404.6.

The Nifty Pharma index was trading 0.03 per cent up at 18622.4.

The Nifty Pharma index closed 0.91 per cent down at 18617.65.

Middle-east tensions affect India markets with 14 stocks having Israel connections. Record-breaking rally faces uncertainty amid geopolitical concerns and rising oil/commodity prices. Analysts cautious about potential interest rate hikes.

Mayuresh Joshi shares insights on pharma and telecom sectors, focusing on key players like Sun Pharma, Dr Reddy's, Bharti Hexacom, and Exide. The discussion also includes Vodafone's FPO and the potential of Li-Ion battery makers.

The Nifty Pharma index closed 1.72 per cent down at 18788.65.

Foram Parekh shares insights on CDMO companies' positive outlook post-Covid correction, potential impact of Biosecure Law, concerns about Laurus's earnings improvement, Sun Pharma's specialty sales focus, and recommendations for pharma sector growth with Lupin and Dr Reddy's.

Indian indices dropped on U.S. inflation concerns. TCS to report Q4 results today. Sun Pharma, Asian Paints, Kotak Bank, NTPC, Maruti top laggards.

According to data sourced from Prime Database, there are 28 non-India expat CEOs among the 2,521 CEOs cumulatively appointed by 2,048 listed companies at end of FY24. The number of expat CEOs has hovered around the same levels over the past decade with several being individuals of Indian origin.

Sensex and Nifty rise. Paytm CEO change and PB Fintech's new subsidiary affect stock prices. TCS to kickstart the quarterly results season. Global market factors influence trading sentiments.

The Nifty Pharma index closed 0.19 per cent down at 19182.3.

Indian shares rose as central bank rates remained stable. Nifty and Sensex gained 0.8%. HDFC Bank performed well. Analysts expect a sideways market. US markets closed higher, while European stocks fell due to Fed comments. Nagaraj Shetty says "the near-term trend of Nifty remains positive and the ongoing range movement is suggesting the possibility of sharp swing movement on either side. Hence a range expansion could be watched around 22600 and 22300 levels on either side.

The Nifty Pharma index closed 0.19 per cent up at 19160.75.

Indian indices reach record highs ahead of RBI's decision. HDFC Bank reports strong growth. Power Grid, Axis Bank, Kotak Bank, Avenue Supermarts, KEC International show positive movement.

Benchmark equity indices closed slightly lower on Tuesday due to mixed global cues. ICICI Bank, Kotak Bank, and IT stocks dragged the market. Sensex fell 111 points to settle at 73,904, while Nifty dropped 9 points to end at 22,453. The market capitalisation of all listed companies on the BSE surged by Rs 2.42 lakh crore to Rs 395.57 lakh crore. The market breadth was skewed in favour of the bulls.

Nifty has a short-term bottom at 21,710 and has its eyes set on a new all-time high with a potential to stretch higher till 23,000–23,100 from a one-month perspective.

Brokerage firm HSBC maintained a buy rating on Sun Pharma, Citigroup recommended a buy rating on ICICI Bank, JPMorgan has an overweight rating on Bajaj Finance and CLSA recommended a buy rating on Avenue Supermarts.

According to analysts, profit-taking may resume until the index decisively reclaims 22,200.

Some of these PE-owned platform companies include Advent International-led Cohance Lifesciences / Suven Pharma, PAG and CX Partners-funded Sekhmet Pharmaventures, and Carlyle-backed Viyash Lifesciences and Sequent Scientific (animal API manufacturer).

Indian Foundation for Quality Management, led by prominent industry figures, strives to enhance quality and innovation in Indian businesses, aiming to compete globally and unlock their true potential.